Comparison of health-related quality of life of children during maintenance therapy with acute lymphoblastic leukemia versus siblings and healthy children in India.

Abstract:

:Data on quality of life (QOL) specifically in maintenance therapy of acute lymphoblastic leukemia (ALL) are minimal. This study was done to assess various items listed in domains of QOL (physical, emotional, social and school health domains) of children with ALL during maintenance therapy, and compare the same with those of their siblings and other healthy children. Forty children on maintenance therapy of ALL, 40 siblings and 40 healthy children were assessed for QOL by child self-report using PedsQL 4.0 Generic Core in the local language. Means were computed and compared for each domain with one-way analysis of variance (ANOVA), wherein higher values reflected better QOL. Overall QOL of children with ALL in maintenance therapy (77.16 ± 10.98) was significantly poorer than that of siblings (93.56 ± 4.41) and healthy children (93.02 ± 3.76) (p < 0.001), but their abilities of self-care, household work, exercise, attentiveness, memory and homework were unaffected. There was significantly higher absenteeism due to sickness and hospital visits, and increased emotional problems (fear, anger, sleeping problems) among children with ALL. In the social health domain, children with ALL reported difficulty in maintaining friendships and competing. QOL of siblings was as good as that of healthy children in physical, social and school health domains, but they had increased emotional problems such as anger and sadness. Healthy children reported significantly higher future worries and bullying than children with ALL and siblings. This study validated that the QOL of children with ALL during maintenance therapy was significantly poorer than that of siblings and healthy children. The study identified various items in each domain of QOL that were affected in these children, and thus would assist in guiding healthcare professionals to focus on these specific items so as to improve their overall QOL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Bansal M,Sharma KK,Vatsa M,Bakhshi S

doi

10.3109/10428194.2012.736985

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

1036-41

issue

5

eissn

1042-8194

issn

1029-2403

journal_volume

54

pub_type

杂志文章
  • The presence of circulating clonal CD19+ cells in multiple myeloma.

    abstract::Multiple myeloma (MM) is a B-cell malignancy characterized by the expansion of mature plasma cells (PC) localized in the bone marrow (BM). Several studies have identified circulating clonotypic CD19+ cells at a differentiation stage preceding the PC. The level of circulating clonotypic CD19+ cells is highly variable b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097764

    authors: Rasmussen T

    更新日期:2001-11-01 00:00:00

  • Waldenstrom's macroglobulinemia in the era of immunotherapy.

    abstract::Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that presents with symptomatic anemia, thrombocytopenia, constitutional symptoms, extramedullary disease and rarely hyperviscosity syndrome. The presence of both IgM monoclonal protein and ≥10% monoclonal lymphoplasmacytic cells is required for the dia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1711901

    authors: Vaxman I,Gertz M

    更新日期:2020-06-01 00:00:00

  • Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.

    abstract::We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400013134

    authors: Chaoui D,Peffault De Latour R,Legrand O,Marie JP

    更新日期:2005-03-01 00:00:00

  • Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    abstract::High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068053

    authors: Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

    更新日期:1991-01-01 00:00:00

  • Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia.

    abstract::In this report a rare case of spontaneous regression of a long-standing chemotherapy resistant low grade non-Hodgkin's lymphoma (NHL) of follicular small cleaved cell type is described. Extensive bulky lymphadenopathy substantially resolved, 7 months before the diagnosis of acute myelomonocytic leukaemia was establish...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051631

    authors: Grigg AP,Gascoyne RD,Barnett MJ

    更新日期:1996-01-01 00:00:00

  • Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.

    abstract::Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1190974

    authors: Arora R,Press RD

    更新日期:2017-01-01 00:00:00

  • Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.

    abstract::Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (Tregs) in the initial DLBCL biopsy specimens, and have evaluated their prognostic signif...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701824536

    authors: Lee NR,Song EK,Jang KY,Choi HN,Moon WS,Kwon K,Lee JH,Yim CY,Kwak JY

    更新日期:2008-02-01 00:00:00

  • Rapid Remission Induction and Improved Disease Free Survival in Acute Myeloid Leukaemia Using Daunorubicin, ARA-C, and CCNU.

    abstract::Thirty-four patients with acute myeloblastic leukaemia were treated with DAC, a schedule containing the nitrosourea CCNU (lomustine) 200 mg/m2 given on day one of treatment, together with a standard "3 + 7" remission induction schedule of daunorubicin (DR) and cytosine arabinoside (Ara-C). The results were compared wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050988

    authors: Barrett AJ,Treleaven JG,Samson DM,Evans M,Gaminara E,Foadi M,McCarthy DM

    更新日期:1990-01-01 00:00:00

  • Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.

    abstract::Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1101099

    authors: Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

    更新日期:2016-07-01 00:00:00

  • Acute promyelocytic leukemia, hypogranular variant, with uncharacteristic staining with chloroacetate esterase.

    abstract::A diagnosis of the hypogranular variant of acute promyelocytic leukemia (APLv) may be difficult to establish based on cytomorphology alone. However, the great majority of cases have a classical immunophenotype by flow cytometric immunophenotyping (FCI) (CD13+, CD33+, dim CD64+, HLA-DR-, and CD34-) and a classical enzy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097693

    authors: Dunphy CH,Polski JM,Johns G,Evans HL,Gardner LJ

    更新日期:2001-06-01 00:00:00

  • Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.

    abstract::Infection with the Epstein-Barr virus (EBV) is common worldwide. A significant number of infected individuals develop infectious mononucleosis (IM). IM is manifested in most patients as a benign disease with mild symptoms. However, serious complications may develop in a subset of patients. Because EBV-infected B lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809057570

    authors: Wright-Browne V,Schnee AM,Jenkins MA,Thall PF,Aggarwal BB,Talpaz M,Estrov Z

    更新日期:1998-08-01 00:00:00

  • CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

    abstract::We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1352089

    authors: Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

    更新日期:2018-04-01 00:00:00

  • Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.

    abstract::Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1108415

    authors: Dong LH,Zhang LJ,Wang WJ,Lei W,Sun X,Du JW,Gao X,Li GP,Li YF

    更新日期:2016-07-01 00:00:00

  • Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.

    abstract::Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290016944

    authors: Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

    更新日期:2002-04-01 00:00:00

  • Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature.

    abstract::The etiology of non-Hodgkin's lymphoma is unknown in the majority of the cases. Although Epstein-Barr virus, human T-cell leukemia-lymphoma virus and human herpes virus-8 have been established as casual agents in the pathogenesis of specific types of lymphoma, the role of hepatitis C virus (HCV) in lymphomagenesis rem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400007771

    authors: Morgensztern D,Rosado M,Silva O,Santos E,Abdullah S,Goodman M,Hamilton-Nelson K,Rosenblatt J,Lossos I

    更新日期:2004-12-01 00:00:00

  • Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?

    abstract::We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 microg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of C...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009065829

    authors: Dazzi C,Cariello A,Rosti G,Argnani M,Sebastiani L,Ferrari E,Zornetta L,Monti G,Nicoletti P,Baioni M,Salvucci M,Scarpi E,Marangolo M

    更新日期:2000-10-01 00:00:00

  • Gastric stump lymphoma five years after distal gastrectomy.

    abstract::We report the case of a 77-year-old man who developed low grade B cell non-Hodgkin's lymphoma of the gastric stump 5 years after undergoing a distal gastrectomy for benign gastric ulcer. Lymphoma occurring in the post-operative stomach would appear to be very rare, with only 14 previously recorded cases. The median pe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000050034

    authors: Di Cosimo S,Ferretti G,Partenzi A,Manicone AM,D'Aprile M

    更新日期:2003-02-01 00:00:00

  • Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

    abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.963080

    authors: Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

    更新日期:2015-06-01 00:00:00

  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

    abstract::Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/1042819031000063462

    authors: George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

    更新日期:2003-10-01 00:00:00

  • Study of specific genetic and epigenetic variables in multiple myeloma.

    abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.528095

    authors: Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

    更新日期:2010-12-01 00:00:00

  • Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

    abstract::We report results of a randomized, phase III study of ofatumumab versus physicians' choice treatment in patients with bulky fludarabine-refractory chronic lymphocytic leukemia and explore extended versus standard-length ofatumumab treatment. Patients (79 ofatumumab, 43 physicians' choice) completed a median 6 (ofatumu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.3109/10428194.2015.1122783

    authors: Österborg A,Udvardy M,Zaritskey A,Andersson PO,Grosicki S,Mazur G,Kaplan P,Steurer M,Schuh A,Montillo M,Kryachok I,Middeke JM,Kulyaba Y,Rekhtman G,Gorczyca M,Daly S,Chang CN,Lisby S,Gupta I

    更新日期:2016-09-01 00:00:00

  • Targeting oncoproteins for degradation by small molecules in myeloid leukemia.

    abstract::Oncoproteins play a vital role in the pathogenesis of myeloid leukemia. Most targeted therapies for myeloid leukemia are small molecules or monoclonal antibodies that inhibit the activity of the oncoproteins. However, leukemia cells often develop resistance to these drugs through overexpression of the target protein a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1403600

    authors: Lei H,Wang W,Wu Y

    更新日期:2018-10-01 00:00:00

  • SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.

    abstract::The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1121257

    authors: Kuci V,Nordström L,Conrotto P,Ek S

    更新日期:2016-08-01 00:00:00

  • A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.

    abstract::Treatment options for patients who relapse following autologous transplantation for Hodgkin's lymphoma are limited. There are anecdotal reports of lengthy remissions following second autologous procedures, although treatment-related toxicity can be significant. We report a single centre experience of second autologous...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701216394

    authors: Thomson KJ,Peggs KS,Blundell E,Goldstone AH,Linch DC

    更新日期:2007-05-01 00:00:00

  • Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.

    abstract::Relapse represents the main cause of treatment failure after allogeneic stem cell transplant (allo-SCT). The detection of minimal residual disease (MRD) by multiparametric flow cytometry (MFC), chimerism, cytogenetics and molecular analysis may be critical to prevent relapse. Therefore, we assessed the overall agreeme...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.789508

    authors: Rossi G,Carella AM,Minervini MM,Savino L,Fontana A,Pellegrini F,Greco MM,Merla E,Quarta G,Loseto G,Capalbo S,Palumbo G,Cascavilla N

    更新日期:2013-12-01 00:00:00

  • Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.

    abstract::There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006277

    authors: Lee HK,Wilder RB,Jones D,Ha CS,Pro B,Rodriguez MA,Romaguera JE,Cabanillas F,Rodriguez J,Cox JD

    更新日期:2002-09-01 00:00:00

  • The late adverse events of rituximab therapy--rare but there!

    abstract::Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902934944

    authors: Ram R,Ben-Bassat I,Shpilberg O,Polliack A,Raanani P

    更新日期:2009-07-01 00:00:00

  • Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells.

    abstract::CD95 (Fas/Apo-1) mediates apoptosis in cells of various types. Expression of CD95 and its function were investigated in myeloma cells and most plasma cell lines have been found to be CD95-positive. Anti-CD95 antibody induced apoptosis in these cell lines in a manner dependent on intensity of CD95 expression. Bel-2 exp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609045712

    authors: Hata H,Matsuzaki H,Takeya M,Takatsuki K

    更新日期:1996-12-01 00:00:00

  • Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.

    abstract::We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1509316

    authors: Eren R,Karişmaz A,Karataş D,Doğu MH,Altindal Ş,Yokuş O,Suyani E

    更新日期:2019-03-01 00:00:00

  • Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.

    abstract::In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by i...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909167393

    authors: Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

    更新日期:1999-01-01 00:00:00